Illuminating the Importance of Pulmonary Arterial Compliance in Pulmonary Hypertension

1. Lamoth F, Lewis RE, Walsh TJ, Kontoyiannis DP. Navigating the uncertainties of covid-19-associated aspergillosis: a comparison with influenza-associated aspergillosis. J Infect Dis 2021;224:1631–1640. 2. Vanderbeke L, Jacobs C, Feys S, Res endiz-Sharpe A, Debaveye Y, Hermans G, et al. A pathology-based case series of influenzaand COVID-19-associated pulmonary aspergillosis: the proof is in the tissue. Am J Respir Crit Care Med 2023;208:301–311. 3. Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al.; European Confederation of Medical Mycology; International Society for Human Animal Mycology; Asia Fungal Working Group; INFOCUS LATAM/ISHAM Working Group; ISHAM Pan Africa Mycology Working Group; European Society for Clinical Microbiology; Infectious Diseases Fungal Infection Study Group; ESCMID Study Group for Infections in Critically Ill Patients; Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy; Medical Mycology Society of Nigeria; Medical Mycology Society of China Medicine Education Association; Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology; Association of Medical Microbiology; Infectious Disease Canada. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 2021;21:e149–e162. 4. Verweij PE, Rijnders BJA, Br€ uggemann RJM, Azoulay E, Bassetti M, Blot S, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intens Care Med 2020;46:1524–1535. 5. Kula BE, Clancy CJ, Hong Nguyen M, Schwartz IS. Invasive mould disease in fatal COVID-19: a systematic review of autopsies. Lancet Microbe 2021;2:e405–e414. 6. Fortarezza F, Boscolo A, Pezzuto F, Lunardi F, Jes us Acosta M, Giraudo C, et al. Proven COVID-19-associated pulmonary aspergillosis in patients with severe respiratory failure. Mycoses 2021; 64:1223–1229. 7. Casalini G, Giacomelli A, Galimberti L, Colombo R, Ballone E, Pozza G, et al. Challenges in diagnosing COVID-19-associated pulmonary aspergillosis in critically ill patients: the relationship between case definitions and autoptic data. J Fungi (Basel) 2022;8:894. 8. Bartoletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Bussini L, et al. Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: a prospective study. Clin Infect Dis 2021;73: e3606–e3614. 9. Chong WH, Saha BK, Neu KP. Comparing the clinical characteristics and outcomes of COVID-19-associate pulmonary aspergillosis (CAPA): a systematic review and meta-analysis. Infection 2022;50:43–56. 10. Rouz e A, Martin-Loeches I, Nseir S. COVID-19-associated pulmonary aspergillosis: an underdiagnosed or overtreated infection? Curr Opin Crit Care 2022;28:470–479. 11. Fekkar A, Lampros A, Mayaux J, Poignon C, Demeret S, Constantin JM, et al. Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU. Am J Respir Crit Care Med 2021;203:307–317. 12. Shi C, Shan Q, Xia J, Wang L, Wang L, Qiu L, et al. Incidence, risk factors and mortality of invasive pulmonary aspergillosis in patients with influenza: a systematic review and meta-analysis. Mycoses 2022; 65:152–163. 13. Schwartz IS, Friedman DZP, Zapernick L, Dingle TC, Lee N, Sligl W, et al. High rates of influenza-associated invasive pulmonary aspergillosis may not be universal: a retrospective cohort study from Alberta, Canada. Clin Infect Dis 2020;71:1760–1763.